GSK oncology chief says mo-rez data strengthens ADC conviction as phase 3 ramps up
Start here
At ESMO, GSK's head of oncology R&D said new mo-rez data reinforce the company's belief in the antibody-drug conjugate, which is advancing into phase 3 development at an accelerating pace. The comments signal GSK's continued commitment to the ADC class as a pillar of its cancer pipeline. The phase 3 program is expanding, with further data expected to shape the candidate's clinical trajectory.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- news.google.comESMO: GSK cancer R&D chief says mo-rez data ‘reinforces our belief’ in ADC as phase 3 push ramps up - Fierce Biotech
At ESMO, GSK's head of oncology R&D said the mo-rez data reinforce confidence in the ADC as phase 3 development accelerates.
Heat trend for this story
Heat now 8·Peak in the comparable set 10 (Oct 24 07:00)·Change over 24h in the comparable set +1200%·Participants now 2
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.